Serengulam V. Govindan

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan et al. · Oncotarget · 2015 · 474 citations · Full text

Pharmacy, Immunology, Oncology +17

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond et al. · Journal of Clinical Oncology · 2017 · 409 citations

Medicine, Oncology, Pharmacology +12

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Alexander Starodub, Allyson J. Ocean, Manish A. Shah et al. · Clinical Cancer Research · 2015 · 344 citations · Full text

Medicine, Oncology, Pharmacology +17

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Clinical Cancer Research · 2011 · 300 citations · Full text

Medicine, Oncology, Pharmacology +12

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Bioconjugate Chemistry · 2015 · 296 citations

Medicine, Oncology, Pharmacology +17